Hormone Care

Hormone therapy is not a one-size-fits-all treatment. Your initial consultation includes a comprehensive review of your symptoms, medical and surgical history, medications, previous treatments, relevant family history, and individual goals.

For women experiencing perimenopause or menopause, hormone therapy may be considered for symptoms such as hot flashes, night sweats, sleep disruption, and genitourinary symptoms. Your age, time since menopause, personal medical history, and individual risk factors are considered when determining whether treatment is appropriate.

For men, testosterone therapy requires an appropriate clinical evaluation. A diagnosis of hypogonadism should be based on compatible symptoms and consistently low testosterone concentrations, rather than symptoms or a single laboratory value alone.

Receiving a consultation does not guarantee that hormone therapy will be prescribed.

For many women with typical perimenopausal or menopausal symptoms, routine hormone testing is not necessary to diagnose menopause or determine whether menopausal hormone therapy may be appropriate. Hormone levels can fluctuate considerably during perimenopause, so a single level may provide limited useful information. Additional testing may still be appropriate when symptoms, age, medical history, menstrual changes, or another possible medical condition warrants further evaluation.

Evaluation for testosterone deficiency in men is different. Diagnosis requires compatible symptoms along with consistently low testosterone concentrations, and additional testing may be needed to determine the cause.

Any laboratory testing ordered at Maile Health is individualized according to your medical history, symptoms, medications, and proposed treatment.

There is no single laboratory schedule appropriate for every hormone patient.

During the initial optimization period, laboratory testing may be ordered after starting treatment or following a significant treatment change when clinically appropriate. The specific tests and timing depend on the hormone being prescribed, route of administration, symptoms, previous results, medical history, and individual risk factors.

Testosterone therapy requires specific monitoring. Endocrine Society guidance includes testosterone measurement approximately 3–6 months after initiation, hematocrit at baseline and approximately 3–6 months after starting treatment, and then annually once stable. Prostate monitoring is individualized according to age, risk, shared decision-making, and applicable screening recommendations.

For menopausal hormone therapy, routine serial hormone levels are not generally required simply to “optimize” a laboratory number. Clinical response, symptoms, side effects, health history, and appropriate preventive care are important components of follow-up.

Once treatment is stable, laboratory monitoring is individualized and may be performed periodically—often within a 6–12 month framework when clinically appropriate—or sooner if symptoms, medications, health status, or treatment change.

The first four months are designed to establish a treatment plan that is both appropriate and well tolerated.

During this period, we monitor your symptoms, response to treatment, possible side effects, medication use, and clinically appropriate laboratory findings. Treatment may be continued, adjusted, changed, or discontinued based on your response and medical needs.

The goal is not simply to achieve a predetermined hormone level. The goal is to use the lowest appropriate treatment necessary to address your clinical needs while continually considering benefits and risks.

Once your treatment plan is stable, you transition from monthly optimization to periodic maintenance care.

Item descriptionAll prescription hormone therapies have potential benefits, risks, and side effects, and these vary according to the specific medication, dose, route of administration, duration of treatment, and your individual health history.

Menopausal hormone therapy can cause effects such as breast tenderness, bloating, headache, or vaginal spotting or bleeding. Systemic estrogen therapy is also associated with risks that can include blood clots and stroke, and risk varies according to individual characteristics and route of administration. Combined estrogen-progestogen therapy is associated with a small increased risk of breast cancer with use.

If a woman has a uterus and receives systemic estrogen, appropriate progestogen therapy is generally necessary to protect the endometrium from the increased risk associated with unopposed estrogen.

Testosterone therapy has its own potential adverse effects and monitoring requirements, including the possibility of an increased hematocrit. Treatment decisions therefore require appropriate follow-up rather than simply prescribing testosterone based on symptoms.

Your individual benefits, risks, alternatives, and monitoring requirements will be discussed before treatment when applicable.

Not everyone is an appropriate candidate, and contraindications depend upon the therapy being considered.

ACOG states that systemic menopausal hormone therapy is generally not recommended in women with a history of certain conditions, including breast or endometrial cancer, stroke, heart attack, blood clots, or liver disease. Pregnancy is also a contraindication. Individual circumstances sometimes require consultation or coordination with another specialist.

For men, the Endocrine Society recommends against initiating testosterone in several circumstances, including men planning fertility in the near term and certain patients with prostate or breast cancer, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, recent myocardial infarction or stroke, thrombophilia, or certain prostate findings that have not been appropriately evaluated.

Your medical history and individual risk factors will be reviewed before treatment is prescribed.

An abnormal laboratory result does not automatically mean that treatment will be stopped—or that medication should simply be increased or decreased.

Results are interpreted in the context of your symptoms, medications, treatment regimen, previous results, medical history, and overall clinical picture.

Depending on the finding, we may repeat testing, adjust your medication, temporarily hold treatment, order additional testing, or recommend evaluation by your primary care clinician or an appropriate specialist.

Certain abnormalities may make it unsafe to begin or continue a particular therapy until they have been appropriately evaluated.

After completing the initial optimization period and reaching a stable treatment plan, most Maile Health hormone patients transition to maintenance visits approximately every four months.

At these visits, we review how you are feeling, treatment response, possible side effects, medication changes, new diagnoses or health concerns, and any laboratory testing that may be appropriate.

Your actual follow-up schedule may be more frequent when clinically necessary.

Hormone therapy should not simply be prescribed indefinitely without reassessment. For menopausal hormone therapy, ACOG recommends discussing at least annually whether continued therapy remains appropriate based on current symptoms, risks, and benefits.

No. Your consultation, optimization membership, and maintenance visit fees cover professional medical care and management.

Prescription medications and laboratory testing are billed separately. Costs vary depending on the medications prescribed, pharmacy used, testing required, and individual treatment plan.

We will discuss recommended testing and treatment with you so you understand what is being ordered and why.

Please contact Maile Health if you develop a new or concerning symptom, significant side effect, or unexpected change after beginning treatment. Depending on the situation, we may recommend an earlier appointment, laboratory testing, medication adjustment, temporarily holding a medication, or evaluation by another healthcare professional.

Do not wait for a routine follow-up appointment for symptoms that may represent a medical emergency. Chest pain, severe shortness of breath, signs or symptoms of a stroke, symptoms concerning for a blood clot, severe allergic reaction, or another potentially life-threatening condition require immediate emergency medical attention.

Website messaging and patient portal communication are not substitutes for emergency medical care.

Yes. Maile Health provides individualized hormone evaluation and management for appropriate adult women and men.

Women's hormone care may include evaluation and treatment of symptoms associated with perimenopause, menopause, and other clinically appropriate hormonal concerns.

Men's hormone care may include evaluation for testosterone deficiency when symptoms and appropriate diagnostic testing support the diagnosis.

Treatment recommendations, medications, laboratory testing, and monitoring differ between women and men and are individualized for each patient.

No. Symptoms such as fatigue, weight changes, sleep disturbance, mood changes, low libido, and difficulty concentrating can have many potential causes and are not proof of a hormone deficiency.

Hormone therapy is not a universal treatment for aging or every symptom experienced during midlife. When appropriate, we may recommend additional evaluation or treatment rather than assuming hormones are responsible. ACOG similarly cautions against portraying hormone therapy as a cure for every midlife concern.